Predictors of Chest Wall XXXX after Lung Stereotactic Ablative Radiotherapy.

@entity662 @entity1 @entity3604 @entity137 @entity174 @entity5 @entity170
AIMS: To determine the incidence and predictive factors of @entity174 and @entity662 after lung stereotactic ablative radiotherapy (SABR). MATERIALS AND METHODS: @entity1 were treated with lung SABR of 48-60  Gy in four to five fractions. The treatment plan and follow-up computed tomography scans of 289 @entity5 in 239 @entity1 were reviewed. Dose-volume histogram (DVH) metrics and clinical factors were evaluated as potential predictors of @entity137 . RESULTS: The median follow-up was 21.0 months (range 6.2-52.1). Seventeen per cent (50/289) developed a @entity174 , 44% (22/50) were symptomatic; the median time to @entity174 was 16.4 months. On univariate analysis, female gender, @entity170 , @entity5 adjacent (within 5  mm) to the chest wall and all of the chest wall DVH metrics predicted for @entity174 , but only @entity5 location adjacent to the chest wall remained significant on the multivariate model (P  <  0.01). The 2 year @entity174 -free probability for those adjacent to the chest wall was 65.6%. Among those @entity5 adjacent to the chest wall, only @entity170 (P  =  0.02) predicted for @entity174 , whereas none of the chest wall DVH metrics were predictive. Eight per cent (24/289) experienced @entity662 without @entity174 . CONCLUSIONS: None of the chest wall DVH metrics independently predicted for SABR-induced @entity174 when @entity5 location is taken into account. @entity1 with @entity5 adjacent (within 5  mm) to the chest wall are at greater risk of @entity174 after lung SABR, and among these, an additional risk was observed in @entity3604 @entity1 .
